Gene expression profiling tests play a critical role when women with early-stage breast cancer decide whether to have chemotherapy, but many of them do not fully understand what some of the test results mean, new research suggests. Current guidelines for treating early-stage breast cancer result in thousands of women receiving chemotherapy without benefitting from it. A gene expression profiling test can help differentiate women who might benefit from chemotherapy versus those that might not.